| Document |
Document Title |
|
WO/2018/189063A1 |
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8,R 8', R9, R9', X1, X2, X3, X4, X5, X6, X7, X8, X9 and X10 are as described herein, as well as pharmaceutically acceptable salts thereof. Furth...
|
|
WO/2018/189554A1 |
Compounds having the general structure A - L - B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1 B. Pharmaceutical compositions comprising these compounds and meth...
|
|
WO/2018/189065A1 |
The present invention relates to compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof for the use in the treatment or prevention of infections and resulting ...
|
|
WO/2018/187400A1 |
Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
|
|
WO/2018/187740A1 |
Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of ag...
|
|
WO/2018/178397A1 |
The invention relates to the synthesis of amphiphilic amino acid derivatives, in particular to a method for the N-alkylation of an unprotected amino acid or the N-terminus of an oligopeptide substrate, comprising reacting said unprotecte...
|
|
WO/2018/177861A1 |
The present invention relates to tris-aryl-amide derivatives having an anti-heparanase activity, in particular it relates toureido/thioureido/ether tris-aryl-amide derivatives of formula (I). The invention also relates to the use of such...
|
|
WO/2018/161976A1 |
Disclosed in the present invention are a tetrapeptide propylene oxide derivative or a pharmaceutically acceptable salt thereof, as well as a preparation method therefor, and the use thereof. The structure of the tetrapeptide propylene ox...
|
|
WO/2018/162806A1 |
The present invention relates to a compound of formula (I): (I) as defined in the description. The present invention also relates to a method for extracting biological membrane-associated membrane proteins, comprising a step of bringing ...
|
|
WO/2018/164019A1 |
The present invention provides peptides, salts thereof, peptide conjugates, and salts thereof having an anxiolytic-like effect, for example a peptide comprising any amino acid sequence selected from (i) an amino acid sequence SYLPPLTT (S...
|
|
WO/2018/149413A1 |
A CD20-targeted antibody coupling pharmaceutical preparation, specifically a preparation comprising a CD20-targeted antibody coupling medication represented by formula I and an excipient. The antibody coupling pharmaceutical preparation ...
|
|
WO/2018/147517A1 |
The present invention relates to an osteogenic promotion peptide comprising sequence number 1 (AWLNH) or sequence number 2 (PHDL), and a composition, for preventing or treating bone diseases, comprising the peptide. The peptide promotes ...
|
|
WO/2018/147624A1 |
Provided in the present invention are an insulin A-chain derived peptide fragment and a pharmaceutical composition for preventing or treating diabetes or diabetic wounds, containing the same as an active ingredient. The peptide of the pr...
|
|
WO/2018/147458A1 |
The present invention provides a novel compound capable of imparting a sweet taste preferable to a food by enhancing the sweetness of a sweetener such as sucrose. This compound is represented by following formula (I) or a salt thereof.
|
|
WO/2018/140145A1 |
Provided are compositions that include at least one two-dimensional layer of an inorganic compound and at least one layer of an organic compound in the form of one or more polypeptides. Methods of making and using the materials are provi...
|
|
WO/2018/138541A1 |
The present invention relates to a compound of the following formula (I), as well as to a pharmaceutical composition comprising at least one compound of following formula (I) and at least one pharmaceutically acceptable excipient, for us...
|
|
WO/2018/133766A1 |
Disclosed are a preparation and a use of a molecular site targeted and activated kinase inhibitor. Specifically, disclosed is a compound represented by the following formula: Lactobionic acid residue -XAN-PABC-Z or a pharmaceutically acc...
|
|
WO/2018/136843A1 |
The present technology provides methods and medicaments useful for treating prostate cancer and breast cancer. Such methods include administering at least one of cyc/o[Phe-D-Pro-Phe-Trp] and cyc/o[Phe-D-Pro-Phe-D-Τrp] to a subject suffe...
|
|
WO/2018/136198A1 |
Compounds that regulate quorum sensing in Staphylococcal bacteria and in particular in Staphylococcus aureus are provided. Compounds are described in formulas I, II, III, IV, V and VI herein. One or more compounds herein can be employed ...
|
|
WO/2018/130790A1 |
The invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO : 1, said peptide having an amino acid sequence selected from the group consisting of: a) the seq...
|
|
WO/2018/126523A1 |
The invention provides a synthesis method of a proline-histidine cyclodipeptide, comprising: preparing an amino-protected proline-histidine dipeptide methyl ester from histidine and proline, wherein one of histidine and valine is a methy...
|
|
WO/2018/122419A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2018/115924A1 |
The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe- N-Methyl- L-Val-L-Ala-OMe (SEQ ID NO :1 ), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium a...
|
|
WO/2018/117000A1 |
The present invention provides food and beverages which have good flavor as a result of reducing an astringent taste caused by cyclo(aspartyl-glycine) contained therein. According to the present invention, both the cyclo(aspartyl-glycine...
|
|
WO/2018/117140A1 |
The purpose of the present invention is to provide L-alanyl-L-glutamine crystals having a low rough specific volume, and a method for producing same. This invention pertains to L-alanyl-L-glutamine crystals having a rough specific ratio ...
|
|
WO/2018/117186A1 |
The present invention relates to a crystals of glutathione trisulfide dihydrate and a method for producing the same. According to the present invention, for example, by concentrating a solution in which glutathione trisulfide is dissolve...
|
|
WO/2018/113891A1 |
The present invention relates to co-amorphous formulation of a substance and a dipeptide. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous formulation as well as to met...
|
|
WO/2018/118902A1 |
An enzyme-responsive peptide and a method off using such enzyme-responsive peptide are disclosed. An enzyme-responsive peptide, the peptide comprising an amino acid having an α-amino group, an α-carboxylic acid group and a ε-amine gro...
|
|
WO/2018/112648A1 |
The present application relates to a compound of formulae (I), (II) or (III) or a pharmaceutically acceptable salt thereof, methods and uses thereof for treating disorders associated with matriptase activity. (I), (II), (III)
|
|
WO/2018/115183A1 |
The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium...
|
|
WO/2018/109042A2 |
This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which n, R1, R1', R2, R3, R4, R4', and R5-R14 are defined in the specification. The compounds of formula (I) can be used t...
|
|
WO/2018/107236A1 |
The present disclosure relates to antibacterial compounds. In particular, the compounds are for inhibiting the growth of bacteria, particularly Mycobacterium tuberculosis (Mtb), and/or targeting bacteria having phospho-MurNAc-pentapeptid...
|
|
WO/2018/104537A1 |
A 3D structure of a hydrogel for supporting cell growth or for use in sustained drug delivery is formed using peptides and/or peptide derivatives that self- assemble via cross-linking into a stiff gel. The hydrogel structure is formed us...
|
|
WO/2018/104962A1 |
The invention pertains to the synthesis, isolation, and characterization of hemiaminal for selective labeling of peptides, proteins, antibodies, and organic fragments with -C(=0) CH2NH2 and derivatives with -CH2NH2 group over -C(=0) CHRN...
|
|
WO/2018/098571A1 |
It is provided a tumor promoting alternative splicing isoform of PACE4, named PACE4-alt CT, analytes specifically binding to PACE4-alt CT, such as antibodies, and use of same for detecting a cancer, such as prostate cancer. It is also pr...
|
|
WO/2018/102536A1 |
Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
|
|
WO/2018/097741A1 |
Peptidomimetic analogs suitable for use in cancer therapy, or as antagonists of opioid drugs, and suitable application of the compounds are disclosed. The described compounds display cytostatic and cytotoxic effects toward intestinal can...
|
|
WO/2018/095422A1 |
Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a bio...
|
|
WO/2018/081897A1 |
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include S...
|
|
WO/2018/085836A1 |
The present disclosure provides simple β-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof.
|
|
WO/2018/081898A1 |
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinat...
|
|
WO/2018/085415A1 |
Integrin ligands having serum stability and affinity for ανβ6 integrins are described. Compositions comprising ανβ6 integrin ligands having serum stability and having affinity for ανβ6 integrins and methods of using them are als...
|
|
WO/2018/079859A1 |
This cell labeling method is characterized in that a complex, which has acquired membrane affinity as a result of reacting a substrate complex, in which hydrophilic groups are bonded to fluorescent groups, or conjugates of fluorescent gr...
|
|
WO/2018/080349A1 |
The invention relates to peptide chemistry, pharmacology, and medicine, and specifically to a new group of peptides having the property of stimulating sexual and genital function and having increased storage stability. For this purpose, ...
|
|
WO/2018/075885A1 |
Supramolecular structures comprising noncovalently associated peptide amphiphiles and lipids are provided. In particular, provided herein are supramolecular nanostructures of peptide amphiphiles and lipids, co-assembly of which is driven...
|
|
WO/2018/072689A1 |
The present invention provides a stachydrine derivative, a preparation method therefor, and applications thereof in the preparation of drugs for treating cardiovascular and cerebrovascular diseases. The stachydrine derivative is a compon...
|
|
WO/2018/071640A1 |
The invention relates to a peptide of formula (I) R1-Wm-Xn-AA1-AA2-AA3-Yp-Zq-R2, cosmetic or pharmaceutical compositions comprising same and its use, for example, in the reduction of lipid accumulation in the skin, the treatment of cellu...
|
|
WO/2018/070829A1 |
The present invention relates to an expression cassette for preparing a copper peptide and use thereof, and more specifically, to an expression cassette for preparing a copper peptide comprising a polynucleotide sequence encoding a pepti...
|
|
WO/2018/071556A1 |
Provided are methods of identifying, visualizing and purifying proteases from a complex biological sample.
|
|
WO/2018/071761A1 |
A mitochondrial-targeted PARP inhibitor is provided herein, as well as methods of making and using the mitochondrial-targeted PARP inhibitor.
|
